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INTRODUCTION
Collagen crosslinking (CXL) is a promising treatment ap-
plied to delay and stop the progression of keratoconus 
(1-4). On one hand, riboflavin used during treatment acts 
as a photosensitizer; on the other hand, it protects the cor-
neal endothelium from UVA radiation (5, 6). During and sub-
sequent to this treatment, a significant change in corneal 
thickness can be detected (7-10), thus the protective effect 
of riboflavin is likely to fail in some cases. Our goal was to 
assess the changes in the thickness of corneas treated with 
isotonic riboflavin during and 1 year after surgery.
PATIENTS AND METHODS
Inclusion criteria for CXL were the following: keratoco-
nus diagnosed on the basis of the known criteria and the 
Collaborative Longitudinal Evaluation of Keratoconus 
Study (11, 12); age 18 to 45 years; cornea thicker than 
400 µm at the thinnest point; and significant decline in visu-
al acuity and/or keratometric values and corneal pachym-
etry in the past 3-6 months. Further inclusion criteria were 
optically clear cornea and a lack of Vogt striae or anterior 
stromal scarring. Exclusion criteria were dry eye syndrome 
distorting the images captured by Pentacam HR and eye 
pathology other than keratoconus.
Prior to operation, the following data were recorded: age, 
sex, and corneal thickness measured at the apex, the 
pupil center, and the thinnest point of the cornea using 
Pentacam HR (Pentacam HR, Oculus Optikgeräte GmbH, 
Wetzlar, Germany, software version 1.17r139). Pentacam 
HR is the high-resolution version of the former Pentacam. 
Using a monochromatic light source (475 nm) and rotating 
around the optical axis, the camera captures 25 Scheimp-
flug images in 2 seconds while also correcting for small eye 
Purpose: To assess intraoperative and postoperative changes in corneal thickness subsequent to 
riboflavin-UVA (collagen crosslinking [CXL]) treatment.
Methods: Forty-one eyes of 41 patients (mean age 27.97 ± 6.97 years) were treated with CXL technique. 
During treatment, isotonic riboflavin was instilled and corneal thickness measurements were obtained at 
the cornea apex, the thinnest point, and the pupil center at 15 and 30 minutes, then 3 days, 1 week, and 
1, 3, 6, and 12 months after surgery using Pentacam HR and an ultrasound pachymeter.
Results: A decrease in corneal thickness was detected 15 minutes intraoperatively with a value of 108.95 
± 48.6 µm, and 112.35 ± 47.3 µm at 30 minutes (p<0.001). Three days after the operation, no deviation 
was found from the initial values (p = 0.17). No further changes were detected during the follow-up period.
Conclusions: Isotonic riboflavin solution used during CXL treatment resulted in a significant decrease 
in corneal thickness, but its effect had disappeared by postoperative day 3.
Keywords: Collagen crosslinking, Corneal thickness, Isotonic riboflavin, Pentacam HR
Accepted: August 16, 2013
© 2013 Wichtig Editore - ISSN 1120-67212
Corneal thickness after collagen crosslinking
movements. For each examination, 3 of these complete 
images were captured of every eye and only automatically 
captured images with no distortion (such as blinking) were 
included. Additionally, ultrasound measurements were 
carried out at the center of the cornea at each visit, us-
ing an ultrasound pachymeter (PachPen; Accutome Inc., 
Malvern, Pennsylvania, USA). 
Surgical technique
Topical anesthesia was performed by administering tet-
racaine hydrochloride eyedrops 15 minutes before the 
operation and every 5 minutes until the end of the op-
eration. The patient was placed under the operating 
microscope and a lid speculum was inserted, the epi-
thelium was marked in the inferior paracentral area to be 
treated (diameter 8-9 mm), and the epithelium was re-
moved with a blunt spatula. Before starting UVA irradia-
tion, the cornea was instilled with riboflavin 0.1%, dextran 
500 20% solution for 15 minutes (single-use isotonic eye-
drops; Medio Cross Medizin Produkte GmbH, Rostock, 
Germany) with a frequency of every 5 minutes for the 
drops. In cases of corneas with a central corneal thick-
ness (CCT) of under 400 µm, we used hypotonic ribofla-
vin solution (single-use hypotonic eyedrops; Medio Cross 
Medizin Produkte GmbH) for 1 hour before irradiation to 
swell the cornea. Then the cornea was exposed to a UVA 
370-nm light (In-Pro CCL-Lix UV, Norderstadt, Germany) 
for 30 minutes at an irradiance of 3.0 mW/cm² (5.4 J/cm2). 
During UVA exposure, isotonic riboflavin drops were con-
tinued every 2 minutes or more often if the corneal surface 
appeared visibly dry.
After the first 15-minute treatment, the cornea was rinsed 
with saline to prevent riboflavin altering measurement val-
ues and topical anesthetics were used as most patients 
complain of eye sensitivity at this stage. The demon-
strating 15-minute Pentacam HR images were captured 
at this stage. In one case, intraoperative images were 
captured also with a Visante optical coherence tomo-
graph (Visante OCT, Carl Zeiss Meditec, Jena, Germany). 
Then riboflavin UVA treatment was continued for a fur-
ther 15 minutes with instillation every 2 minutes. After 
treatment, the eye surface was washed with antibiotic 
drops, a process that was followed by the placement of 
a bandage soft contact lens (Air Optix Night and Day, 
Alcon, Fort Worth, Texas, USA). Postoperatively, antibiot-
ic (3 mg/mL tobramycin) drops 5/day were administered 
for 5 days, corticosteroid (1 mg/mL flurometholone) drops 
5/day for a minimum of 1 month starting at postopera-
tive day 5. The bandage contact lens was removed on 
postoperative day 3, at which point slit-lamp examination 
was performed to confirm the presence of complete cor-
neal re-epithelization. Routine examinations were per-
formed 3 days, 1 week, 1 month, 3 months, 6 months, 
and 12 months postoperatively.
All treatments were carried out by the same experienced 
operator. All patients were informed about the details of the 
examinations and the operation and signed an informed 
consent. All examinations were conducted according to 
the protocol of the Declaration of Helsinki.
Statistical analysis was performed with MedCalc 10.0. 
Descriptive statistical results were described as mean, 
standard deviation (SD), and 95% confidence interval 
(95% CI) for the mean. A Wilcoxon test was carried out 
for comparisons between groups or variables, and a 
Spearman rank test for correlation. A p value below 0.05 
was considered statistically significant.
RESULTS
Forty-one eyes of 41 patients were treated with CXL 
technique. The mean age was 27.97 ± 6.97 years (95% 
CI 25.77-30.17, range 18-44.06 years). 
Compared to the preoperative data, corneal thickness 
was significantly thinner at 15 minutes and 30 minutes 
during treatment (p<0.001) using Pentacam HR. The 
average decrease was 108.95 ± 48.6 µm at 15 minutes 
and 112.35 ± 47.3 µm at 30 minutes intraoperatively 
using Pentacam HR. The rate of the decrease showed 
no correlation with the initial corneal thickness values 
(r = 0.16; p = 0.7). Three days after the operation, no 
statistically significant deviation was found between the 
measured points and the initial values using Pentacam 
(p = 0.17) and ultrasound device (p = 0.32). No further 
changes were detected during the follow-up period. Our 
corneal pachymetry data are summarized in Tables I  
and II and illustrated in Figure 1. Intraoperative im-
ages were captured by Pentacam HR and Visante OCT 
(Fig. 2). A hyper-reflective corneal tissue zone can be 
clearly seen in Pentacam HR images but is not distinctly 
visible in Visante OCT. 
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TABLE I -  CORNEAL THICKNESS MEASUREMENTS IN µM AT THE CORNEAL APEX, THE THINNEST CORNEAL POINT (MIN), 
AND PUPIL CENTER (PUPIL) PRIOR TO COLLAGEN CROSSLINKING, INTRAOPERATIVELY, AND IN THE POSTOP-
ERATIVE FOLLOW-UP PERIOD, USING PENTACAM HR
Mean SD 95% CI Minimum Maximum
Preoperative
 Apex 463.61 53.454 446.513-480.703 299.33 564.67
 Min 446.74 51.692 430.209-463.273 298 559.67
 Pupil 472.83 49.577 456.978-488.689 321.33 569.33
15 minutes
 Apex 354.66 63.088 334.482-374.835 199.67 468.33
 Min 341.99 65.61 321.009-362.975 165.67 459
 Pupil 359.13 64.101 338.633-379.634 192 481.67
30 minutes
 Apex 351.25 53.277 334.212-368.289 233.67 458
 Min 336.43 59.024 317.556-355.310 208.67 453
 Pupil 354.16 55.581 336.383-371.934 240 464
3 days
 Apex 484.53 78.136 459.201-509.859 275.67 666.33
 Min 466.56 81.392 440.171-492.940 222.67 646.33
 Pupil 490.33 76.608 465.500-515.167 295.33 667.67
1 week
 Apex 467.45 62.92 447.057-487.849 298.33 592
 Min 450.72 60.394 431.141-470.296 290.67 561
 Pupil 476.83 59.366 457.585-496.073 322 593.67
1 month
 Apex 456.68 55.596 438.895-474.456 285.33 560
 Min 441 53.345 423.939-458.060 276.67 540
 Pupil 467.25 49.241 451.502-482.998 334 570
3 months
 Apex 453.78 53.843 434.369-473.194 291.33 567
 Min 437.65 52.382 418.759-456.531 283.67 558.33
 Pupil 467.24 49.303 449.464-485.015 327.67 573.33
6 months
 Apex 444.29 53.633 422.154-466.432 296.33 526.33
 Min 429.39 51.364 408.186-450.589 293 506
 Pupil 457.76 47.916 437.983-477.540 329.67 532.67
12 months
 Apex 441.02 55.775 412.343-469.696 294 523
 Min 426.35 52.725 399.244-453.462 289.67 502.67
 Pupil 454.59 49.264 429.258-479.917 329.33 531
CI  =  confidence interval; SD = standard deviation.
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DISCUSSION
The purpose of CXL treatment is to establish new chemical 
bonds in corneal stroma induced by riboflavin and 370-nm 
UVA light. On one hand, riboflavin acts as a photosensi-
tizer during treatment; on the other hand, it protects the 
areas below the treatment zone from the effects of the UVA 
radiation (5, 6). The aim of the treatment is to increase the 
rigidity and the biomechanical strength of the cornea. This 
therapy has been widely used for the treatment of pro-
gressive keratoconus (1-4), although its other diagnostic 
abilities are also well-known (13). Both objective (14, 15) 
and subjective (16) improvements were reported in eyes 
with keratoconus after CXL treatment, even in subjects un-
der 18 (17).
As collagen bonds are established at a depth of 250- 
350 µm in the anterior stroma, called the treatment zone 
(5, 18-21), and for the protection of the endothelium, 
a minimum of 400 µm stromal thickness is suggested 
(5, 22). However, according to other publications, a mini-
mum of 330 µm of initial thickness is also sufficient for CXL 
after corneal swelling (23). Transepithelial CXL or custom-
ized pachymetric guided epithelial debridement may be 
beneficial in cases where corneal thickness is thinner than 
400 µm (24, 25). Our study comprised 2 patients who had 
refused any surgical procedure, where the initial corneal 
thickness value was under 300 µm. According to our ex-
perience, it is safe to use isotonic riboflavin after corneal 
swelling is achieved with hypotonic riboflavin solution. 
However, in our practice a preoperative treatment limit of 
at least 400 µm is used.
Our study aimed to reveal the process of how the well-
known changes in corneal thickness after CXL therapy 
TABLE II -  CORNEAL THICKNESS MEASUREMENTS IN 
µM AT THE CENTER OF THE CORNEA PRIOR 
TO COLLAGEN CROSSLINKING, INTRAOP-
ERATIVELY, AND IN THE POSTOPERATIVE 
FOLLOW-UP PERIOD, USING AN ULTRA-
SOUND PACHYMETER
Mean SD 95% CI Mini-
mum
Maxi-
mum
Preoperative 475.80 58.763 457.007-494.593 317 590
15 minutes 339.88 57.529 321.476-358.274 205 460
30 minutes 330.03 44.748 315.714-344.336 207 460
3 days 474.71 69.928 450.693-498.735 311 580
1 week 475.80 56.937 457.591-494.009 310 565
1 month 470.49 56.764 451.560-489.413 310 567
3 months 468.74 54.216 447.294-490.188 320 557
6 months 463.36 48.423 443.372-483.348 325 555
12 months 460.12 54.690 431.999-488.237 325 554
CI = confidence interval; SD = standard deviation.
Fig. 2 - Pentacam HR and Visante optical coherence tomography 
(OCT) images captured at 15 minutes during collagen crosslinking 
treatment. Hyperreflective corneal tissue zone can be seen in Pen-
tacam HR pictures (right) and not distinctly visible in Visante OCT 
pictures (left). 
Fig. 1 - Mean corneal thickness changes at 15 minutes and 
30 minutes during collagen crosslinking and 3 days, 1 week, 1, 3, 
6, and 12 months after treatment. In every case, thickness mea-
surements at the corneal apex (apex), pupil center (pupil), and the 
thinnest point of the cornea (min) were recorded. CCT = central 
corneal thickness.
[Author: Please provide high res images fig. 1 & 2.]
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(7, 10, 26, 27) occur at a less investigated intraoperative 
stage and in the follow-up period. 
Administering isotonic riboflavin, Greenstein et al (28) mea-
sured pupil, apical, and the thinnest corneal thickness as 
being 23-24.6 µm thinner 1 month after treatment using 
Scheimpflug analysis. At 1 year, apex and pupil center 
thicknesses returned to the baseline; however, the thin-
nest pachymetry remained slightly lower than baseline 
and similar values were found for pupil, apex, and thin-
nest pachymetry thicknesses (28). The gradually increas-
ing values did not reach preoperative readings until 1 year 
after the operation. Data were compared with ultrasound 
pachymetry, but were analyzed only preoperatively (28). A 
number of other studies reported changes in corneal thick-
ness after CXL treatment and, in every case, a decrease 
was observed (7-10, 26, 27). Despite the findings men-
tioned above, corneal thickening was reported 3 days after 
CXL in rabbit cornea, which ceased only 1 week later (29). 
So it seems that corneal tissues may react differently to the 
treatment due to structural differences.
It has also been suggested that changes in corneal thick-
ness observed using Scheimpflug analysis can be an 
artefact (30, 31) resulting from postoperative corneal haze 
(8, 9, 32). In our study, ultrasonic measurements were 
also carried out subsequent to treatments, which showed 
similar results preoperatively and from 1 week after CXL. 
However, intraoperatively and at the 3-day visit, ultrasound 
pachymetry measured smaller CCT than Pentacam. The 
possibly altered refractive index of crosslinked corneas 
can be the background of this difference.
Results obtained with Scheimpflug analysis and ultrasound 
measurements correlate well with each other. The thinning 
of the cornea and stromal haze can be explained by struc-
tural and physiologic wound-healing changes developing 
after treatment (33), though the mechanism of corneal 
re-thickening remains unexplained.
A limitation of our study is that subsequent to de-epithe-
lization no Pentacam HR images were captured. Normal 
epithelial thickness was reported as 53.4 ± 4.6 µm (34), 
a value supported by the data reported by Kymionis et al 
of 43 µm (35). When this mean epithelial thickness is sub-
tracted from the thickness that we measured preopera-
tively, the decrease in the corneal thickness remains highly 
significant (p<0.01). 
During pachymetric measurements, corneal thickness 
was analyzed at the thinnest point and in the pupil cen-
ter. The readings of Henriquez et al (36) showed a mean 
corneal thinning from 56 µm to 13 µm at the thinnest point 
of the cornea 1 and 12 months after treatment. Vinciguerra 
et al (14) found a significantly thinner cornea in the pupil 
center even 1 year after treatment; however, they showed 
no significant change vs the thinnest pachymetry location 
in eyes with keratoconus 1 year after the CXL operation. 
Both authors performed central CXL operation. In our 
study, the corneal thickness returned to the preopera-
tive level on postoperative day 3, which remained stable 
in each of the 3 measured points even at the end of the 
1-year follow-up.
Publications suggest corneal thinning in the early postop-
erative stage, so UVA light can reach corneal endothelium 
intraoperatively. Therefore, hypoosmolar riboflavin solution 
is suggested in order to achieve corneal iatrogenic swelling 
(37), although according to previous research it has only a 
short-term effect and does not even last until the end of the 
treatment (38).
Publications found in the literature clearly describe the 
CCT decrease observed after CXL treatment, though 
only a few and contradicting reports were carried out on 
the characteristics of CCT decrease in the intraoperative 
phase (35, 38, 39). Using isotonic solution, Kymionis et al 
(35) detected a mean 75 µm CCT decrease between epi-
thelial removal and riboflavin instillation with ultrasound 
pachymetry measurements; however, they found no fur-
ther changes in corneal thickness during irradiation. These 
data correlate well with our data regarding the decrease in 
thickness. Kaya et al (38) measured corneal thickness at 
5 different times: the thinnest pachymetry data decreased 
to a mean of 376 µm after the epithelial removal and by 
a mean of 55 µm after the 30-minute application of the 
isotonic riboflavin solution. The 10-minute application of 
hypotonic riboflavin resulted in the cornea thickening by a 
mean of 59 µm. Ten and 30 minutes after the instillation of 
isotonic riboflavin solution, the thinnest pachymetric read-
ings showed a decrease with a value of 50 and 65 µm. 
Holopainen and Krootila (39) measured corneal thickness 
both preoperatively and postoperatively using ultrasound 
pachymeter and found a thinning of a mean 87 µm dur-
ing the 1-hour operation. Depending on the initial corneal 
thickness, they administered isotonic or hypotonic solu-
tion. Compared to the preoperative CCT, they reported a 
significantly lower value 1 month after the operation and 
found the same value 6 months after treatment. In our 
study, corneal thickness reached the initial value 3 days 
after treatment. 
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In summary, a significant decrease in corneal thickness 
can be observed during CXL treatment applied for treat-
ing keratoconus. However, this change is temporary and 
the value measured initially is reached 3 days after treat-
ment. Further investigations are suggested in order to 
determine whether this change may have any conse-
quences or whether it is of any significance.
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